Long Term Study of Protective Mechanisms of Human Adipose Derived Mesenchymal Stem Cells on Cisplatin Induced Kidney injury in Sprague-Dawley Rats

Elhusseini FM1,5, Saad M-AAA2,3, Anber N1, Elghannam D1, Sobh M-A5a, Alsaaed A6, El-dusoky S6, Sheashaa H6, Abdel-Ghaffar H7, Sobh MA5b,6

Background/Aims: Long-term evaluation of cisplatin induced nephrotoxicity and the probable renal protective activities of stem cells are lacking up until now. We evaluated the early and long-term role of human adipose derived mesenchymal stem cells (ADMSCs) in prevention or amelioration of cisplatin induced acute kidney injury (AKI) in Sprague-Dawley rats. For this, we determined the kidney tissue level of oxidative stress markers in conjunction with a renal histopathological scoring system of both acute and chronic renal changes.

Methods: This study used eighty Sprague-Dawley (SD) rats weighing 250-300g. They were assigned into four equal groups (each group n=20): (I) Negative control group, rats injected with single dose of 1 ml normal saline. (II) Positive control cisplatin, rats injected with a single dose of 5 mg/kg I.P in 1 ml saline. (III) Cisplatin and culture media group, rats injected with 0.5 ml of culture media single dose into the tail vein and (IV) Cisplatin and ADMSCs group, rats injected with a single dose of 0.5 ml of culture media containing 5 x10^6 ADMSCs into the tail vein one day after cisplatin administration. Each main group was further divided according to the timing of sacrifice into four subgroups (each subgroup n=5). Rats in the subgroup A were sacrificed after 4 days; subgroup B were sacrificed after 7 days; subgroup C were sacrificed after 11 days; and subgroup D were sacrificed after 30 days. Before sacrifice, 24 hrs.-urine was collected using a metabolic cage. Renal function was evaluated through blood urea nitrogen (BUN), serum creatinine and creatinine clearance. Kidney tissue homogenate oxidative stress parameters, Malondialdehyde (MDA), Superoxide dismutase (SOD) and Glutathione (GSH) were determined. In addition, histopathological analysis for active injury, regenerative and chronic changes was performed.

Results: ADMSCs were characterized and their capability of differentiation was proved. Cisplatin induced a significant increase in plasma creatinine and tissue MDA and induced a decrease in SOD, GSH and creatinine clearance. ADMSCs attenuated these changes. Cisplatin resulted in prominent histopathological changes in the term of tubular necrosis, atrophy, inflammatory cells infiltration and fibrosis. ADMSCs significantly lowered the injury score at day 4, 7, 11 and 30 with marked regenerative changes starting from day 4 and limited fibrotic score at day 30.

Conclusion: ADMSCs have both protective and regenerative abilities with consequent limitation of the development of renal fibrosis after the cisplatin induced acute tubular necrosis, largely through an anti-oxidative activity.

Key Words: Acute kidney injury in rats, Renal fibrosis, Cisplatin, Adipose mesenchymal stem cells, Oxidative stress markers.

Introduction

Cisplatin is a chemotherapeutic agent largely used for the treatment of many human malignancies. However, nephrotoxicity is one of the serious adverse effects that limit its clinical use. Cisplatin has multiple cellular targets; so blocking its effect on a single target may only offer moderate protection against nephrotoxicity[1]. Hence, to alleviate cisplatin nephrotoxicity a strategy to tackling multiple cellular levels is important. Several potential advantages through cell therapy over specific drugs or growth factors in the treatment of many disorders as AKI have been demonstrated[2,3].

Mesenchymal stem cells (MSCs) are multi-potent adult stem cells harbouring multi lineage differentiation potential, paracrine and immunosuppressive properties that make MSCs an ideal candidate cell type for immunomodulation and regeneration[4].

Adipose tissue contains different cell types besides adipocytes, including adipose derived mesenchymal stem cells (ADMSCs), which are emerging as cellular therapy tools[5]. Plasticity of ADMSCs and their capability of differentiation into cells of mesodermal origin, such as adipocyte, osteocyte, chondrocyte and myocyte lineages have been demonstrated[6]. In addition to their easy availability as a human source and the absence of ethical restriction, this source has immense clinical importance in regenerative medicine.

Some previous studies have reported the effect of MSCs on cisplatin induced AKI. All of them used a small sample size. One used rat bone marrow MSCs[7] and others used human ADMSCs[8,9]. The unique feature of our study was the use of large sample size, long-term follow up and assessment of oxidative stress markers levels for evaluating an early protective and late ameliorating effect of ADMSCs on cisplatin induced kidney injury.

Materials and methods

The Local Ethical Committee, Faculty of Medicine and Mansoura University, Egypt approved the experimental protocol.

Received 19 Sep 2015; accepted 04 Mar 2016; published online: 30 May 2016

Copyright © Journal of Stem Cells and Regenerative Medicine. All rights reserved
ADMSCs were isolated from human abdominal fat tissue collected during liposuction surgery at Plastic Surgery Hospital, Faculty of Medicine, Mansoura University, Egypt. All eligible patients or their guardians provided their written informed consent and permission to isolate the MSCs from fat tissues. The culture methods were based on the method of Bunnell et al.[10]. The tissue was washed with phosphate-buffered saline (PBS) containing 1% antibiotic–antimycotic solution (Thermo scientific, USA) thrice, until all blood vessels and connective tissue appear liberate. This step was followed by digestion with trypsin (Sigma-Aldrich, USA) 0.125 % at 37 °C with shaking at 100 rpm (3ml for each 1 gm Adipose tissue) for 60 min. The tissue digestion was checked every 15 min and the tissue digestion vessel was shaken vigorously. After digestion, trypsin activity was neutralized by adding equal volume of Dulbecco’s modified Eagle’s medium (DMEM; Lonza, Verviers, Belgium) containing 10% fetal bovine serum (FBS; Thermo scientific, USA), to the tissue sample. The cell suspension was filtered through 100 µm filters (BD Falcon, USA) for avoiding the solid aggregates. The sample was then centrifuged at 2000 rpm for 5 min at room temperature. The samples were taken out from the centrifuge and shaken vigorously to complete the separation of the stromal cells from the primary adipocytes. The centrifugation step was repeated and the supernatant was removed without disturbing the cells. The pellet was suspended in 1 ml of lysis buffer (Promega, Germany) to lyse the RBCs and then incubated for 10 min. Then the pellet was washed with 10 ml of PBS+1% antibiotic–anti mycotic and centrifuged at 2000 rpm for 5 min. Supernatant was removed and the cell pellet was suspended in DMEM with 20% FBS and 1% antibiotic-anti mycotic solution and 25-cm² culture flask and maintained in an incubator supplied with humidified atmosphere of 5% CO₂ at 37°C.

Cell culture

After a day, non-adherent cells were removed by two to three washes with PBS and adherent cells were further cultured in complete medium. The medium was changed every 3 days until the monolayer of adherent cells reached 70-80% confluence. Then, we used trypsinization for cell splitting by employing trypsin-EDTA solution (0.25%, sigma Aldrich, USA) for passage 1. The number of cells was evaluated using hemocytometer and cellular viability was assessed by the Trypan Blue exclusion test. Each 250-300×10⁴ cells were inoculated in a 75 cm² culture flask which was incubated at 37°C and 5% CO₂. Cell cultivation was maintained up to the third passage.

Phenotypic analysis with Flow cytometry

Cells were characterized using cell surface mesenchymal markers by fluorescence-activated cell sorting (FACS) analyses. The cells were stained with different fluorescent labeled monoclonal antibodies (mAbs), CD29 and CD90 (eBioscience), CD 13, CD 105, CD34 and CD 34 as hematopoietic lineages markers. In brief, 5×10⁶ cells (in100 µl PBS/0.5% BSA/2mM/L EDTA) were mixed with 10 µl of the fluorescent labeled mAb and incubated in the dark at 2-8 °C for 30 min. They were then washed twice with PBS containing 2% BSA. The pellet was re-suspended in PBS and analyzed immediately using flow cytometry. The fluorescence intensity of the cells was evaluated by EPICS-XL flow cytometry (Coulter, Miami, FL, USA).

Colony forming unit-fibroblast (CFU-F)

Fibroblast colony growth was evaluated in the primary cells grown on tissue culture in six-well dishes[11]. About 100 cells were plated in 100-mm tissue culture dish (Falcon) in complete culture medium. Cells were incubated for 10–14 days at 37 °C in 5% humidified CO₂, washed with PBS and fixed in 95% ethanol for 5 minutes, then incubated for 20–30 minutes at room temperature in 0.5% crystal violet (sigma Aldrich, USA) in 95% ethanol and then the plates were washed twice with distilled H₂O. The plates were dried and the CFU-F units counted.

Differentiation capability of hADMSCs

a) Osteogenic Differentiation:

Passage 3 MSCs were harvested by trypsin digestion as described above. The cells were counted and seeded at a density of 5×10⁵ per well in a 6-well plate. Then at 80% confluence, to four of the wells, osteogenesis differentiation media: DMEM supplemented with 10% FBS, 0.1µM dexamethasone, 50µM Ascorbic acid, 10mM β-glycerol phosphate (Sigma-Aldrich, USA) was added. To the other two wells, complete culture media as negative control[12] was added. The media were changed twice per week for 2-3 weeks. The differentiation potential for osteogenesis was assessed by 40 mM Alizarin Red (pH 4.1) after fixation in 10% neutral buffered formalin[13].

b) Adipogenic Differentiation:

Passage 3 MSCs harvested by trypsin digestion as described above were counted and seeded at a density of 10×10⁵ per well in a 6-well plate, then at 100% confluence. To four of the wells, adipogenesis differentiation media: DMEM supplemented with 10% FBS, 1µM dexamethasone, 500-µM isobutylmethylxanthine (IBMX) 5µg/ml insulin, 200µM Indomethacin (Sigma-Aldrich, USA) was added. To the other two wells, complete culture media as negative control was added. All media were changed twice per week for 2 weeks[12]. The differentiation potential for adipogenesis and formation of intracellular lipid droplets were assessed by Oil-red-O after fixation in 10% neutral buffered formalin[13].

c) Chondrogenesis Differentiation:

MSCs were harvested and 6×10³ cells were centrifuged to form a pellet on the bottom of a 15-ml polypropylene tube (Falcon). The micro mass was cultured in 500µl of chondrogenic medium that consisted of 50 µg/ml ascorbic acid 2-phosphate and 1 ng/ml TGF-β1[12] (Sigma). After 3 weeks of culture, cell clumps were harvested, embedded in paraffin, cut into 3-µm sections and stained for glycosaminoglycans using 0.1% safranin O (Sigma).

Detection by Image J analysis

Twenty different digital images corresponding to four different preparations of osteogenic, adipogenic, chondrogenic differentiated cells and undifferentiated controls were analyzed using Image J 1.42 software on an appropriate threshold. Image J can calculate area and pixel value statistics of user-defined selections and intensity threshold objects. It can measure distances and angles. It can create density histograms and line profile plots[14].

Identification of MSCs differentiation to adipocytes by RT-PCR analysis

MSCs differentiation to adipocytes was further demonstrated by Real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of adipocytic and osteocytic markers expression (Table 1). Total RNA was isolated from MSCs and real-time reverse transcriptase-PCR was performed as described previously[12]. Selective markers and primer sequences were used. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal standard.
Renal anti-injury activity of ADMSCs in cisplatin induced nephrotoxicity

Total RNA extracted from the cultured cells, following the manufacturer’s instructions. For adipogenic differentiation, the cells were assessed using specific Primers identified in Table 1. The RT-PCR procedure performed using the One Step RT-PCR kit, beginning at 50°C for 30 min and 95°C for 15 min for reverse transcription and then followed by 35 cycles. Each cycle consisted of denaturation at 94°C for 1 min, annealing at 57°C for 1 min, elongation at 72°C for 1 min and the final extension at 72°C for 10 min. The amplified DNA fragments visualized through 2% agarose gel electrophoreses then photographed under UV light.

hADMSCs in basic culture conditions expressed adiponectin and adipocyte lipid-binding protein (ALBP).

**Animal Treatment**

Male Sprague-Dawley rats (250–300 g) were maintained in a 12:12-h light-dark cycle in a temperature and humidity-controlled facility. Standard rat chow and water provided. Animal studies were conducted according to the experimental protocol that was approved by the Local Ethical Committee, Faculty of Medicine, Mansoura University. Animals were divided into four equal groups (each group n=20). The negative control group received a single injection of saline intraperitoneally. The positive control group was given a single intraperitoneal injection of cisplatin (10 mg/kg body wt.) and an equal volume of PBS instead of ADMSCs. The ADMSCs group was given a single injection of ADMSCs (5×10⁶ cells) by tail vein. The cisplatin and ADMSCs group received single dose cisplatin and only one dose ADMSCs given at day 1 after cisplatin injection. For long term study on the protective effect of ADMSC against cisplatin AKI, each main group was further divided according to the timing of sacrifice, into four equal subgroups (each subgroup n=5). Subgroup A sacrificed after 4 days; subgroup B sacrificed after 7 days; subgroup C sacrificed after 11 days and subgroup D sacrificed after 30 days. Before sacrifice, 24 hrs.-urine was collected using a metabolic cage. Rats were sacrificed using an over dose of thiopental. Blood samples were collected from the heart immediately centrifuged at approximately 3000 g for 5 min., and then taken for biochemical measurements. The kidneys were removed for histological evaluation.

**Assessment of renal function**

Serum samples were examined for blood urea nitrogen (BUN), serum creatinine, creatinine clearance using Diamond Diagnostics (Egypt) standard diagnostic kits.

**Assessment of Oxidative stress markers**

Kidney tissue homogenate was used for assessment of MDA, SOD, and GSH, using Biodiagnostic Co. (Egypt) for all the groups and subgroups.

**Renal histology and damage scoring**

The left kidney was perfused in a retrograde fashion through the abdominal aorta using saline 0.9% until complete clearance of the perfusion fluid and then 10% neutral buffered formalin for in situ fixation. Renal samples were coded and processed for light microscopic examination. Histopathological changes were analyzed in the different regions of the kidney (cortex, outer strip of outer medulla “OSOM”, inner strip of outer medulla “ISOM” and inner medulla using H&E, periodic acid- Schiff (PAS) reagent and Masson trichrome stains according to a new scoring system (submitted for publication).

### Table 1: Primers for Adipogenic and osteogenic differentiation RT-PCR of human adipose derived mesenchymal stem cells

| Genes                              | Forward Primer               | Reverse Primer               |
|------------------------------------|------------------------------|------------------------------|
| Adipogenic Genes                   |                              |                              |
| Adiponectin                        | TCCTGCCAGTAACAGGGAAG          | GGTTGGCGATTACCGTTTG          |
| Adipocyte lipid-binding protein (ALBP) | TACCTGGAAAACCTTGCCAGGAA      | CCATTCTGCACATGTACCAGGACA     |
| Lipoprotein Lipase                 | CTGCTGGCGTACGAGGAAGT          | GCTGAAAAGTCCTCCATTG          |
| Lipten                             | TGACACAAAAACCTCATCA           | TCATTGGCTATCTGACGAC          |
| Osteogenic Gene                    |                              |                              |
| Osteocalcin                        | ACACACACCCCTATTG               | GATGTGGTCAGCCAAC            |

Copyright © Journal of Stem Cells and Regenerative Medicine. All rights reserved
Active injury changes

These include necrotic tubules and interstitial infiltration by inflammatory cells. Necrotic tubules were scored according to the number of necrotic tubules counted/high power field (HPF) and scored to 1, 2, 3 and 4 corresponding to 1-3, 4-5, 6-10 and >10 necrotic tubules / HPF. The inflammatory cells were scored as 1, 2, 3 corresponding to mild, moderate & severe. The maximum score of active injury is 7.

Regenerative changes

These include presence of mitosis, solid cellular sheets between the tubules, intraluminal cellular proliferation forming solid tubules, tubules lined with large vesicular nuclei and tubules lined by cells having hyperchromatic prominent nuclei and little cytoplasm giving the luminal border a festooned appearance. Each of the solid cellular sheets and solid tubules was counted as 1-2, 3-5 and > 5 / HPF were scored as 1, 2 and 3 respectively. Mitosis was scored as 1, 2 and 3 corresponding to 1-2, 3-5 and > 5 /10 HPF. Tubules with large vesicular nuclei and tubules with basophilic prominent nuclei got score 1, when present and got score 0, if absent. The maximum score of regeneration was 11.

Chronic changes

These include atrophic tubules with flat lining, casts, and thick basement membrane and interstitial fibrosis. The maximum chronicity score was 7; where the number of atrophic tubules /HPF of 1-5, 6-10 and > 10 were scored 1, 2 and 3 respectively. In addition, the percentages of interstitial fibrosis / HPF of 25, 25-50, 50-75 and more than 75 % got scores of 1, 2, 3 and 4 respectively.

Statistical analysis

Data was analyzed using SPSS version 16. Variables were tested for normality of distribution using Kolmogrov-Smirnov test. Both the biochemical and the morphological results were non-parametric. Kruskal-Wallis test was used for comparison. The results are presented as mean± SD. P≤0.05 was considered statistically significant.

Results

Isolation and characterization of human ADMSCs

Human ADMSCs were isolated from human fat tissue that was obtained from abdominal fat of liposuction surgery. Attachment of spindle-shaped cells to tissue culture plastic flask was observed after 1 day of culture of the ADMSCs. After 5 days, spindle-shaped cells reached 80% confluency. Morphology of cells changed gradually with the increase in passage number. Cells became more flat-shaped with increase in passage number (Figure 1A).

Colony forming unit-fibroblast (CFU-F)

CFU-F assay was a suitable tool for evaluating the proliferation and colonogenic capacity of the cells (3rd passage) expanded in culture. The colony number of 100 ADMSCs per 100-mm tissue culture dish was 38 ± 1 (Figure 1 B&C). The ADMSCs isolated from human adipose tissue used in our experiments, were plastic-adherent and capable of extensive proliferation when maintained in their standard culture conditions.

Figure 1: Characterization of human adipose-derived mesenchymal cells (AD-MSCs). (A): Under an inverse microscopy (magnification × 200) cultured mesenchymal stem cell (MSCs) derived from human adipose tissue at passage three were morphologically defined by the fibroblast-like appearance. (B) & (C) Colony forming unit-fibroblast (CFU-F). Photomicrographs of human adipose tissue derived mesenchymal stem cell (MSCs) after one week of culture grew in colonies that contained heterogeneous small spindle-shaped fibroblastoid cells and more rounded cells (A and B original magnification × 100)

Figure 2: hADMSCs differentiation capability. Photomicrographs of mesenchymal stem cells (MSC) derived from human adipose tissue showing differentiative potential. (A) Osteogenic differentiation indicated by the formation of calcium-rich hydroxyapatite detected with Alizarin red and appear as irregular red-orange [magnification × 200]. (B) Adipogenic differentiation apparent after 1 week of incubation with adipogenic induction medium. Between the culture periods of 3±2 weeks, almost all cells contained numerous Oil Red O-positive lipid droplets (C) Chondrogenic differentiation apparent after 1 week of incubation with chondrogenic induction medium. Between the culture periods of 3±2 weeks, almost all cells contained numerous glycosaminoglycans.
Renal anti-injury activity of ADMSCs in cisplatin induced nephrotoxicity

Differentiation capability of hADMSCs

Distinct culture conditions demonstrated the pluripotency of ADMSCs. They enabled cells to differentiate into osteoblasts, adipoblasts and chondroblasts. According to Image J analysis and spectrophotometric analysis, Image J analysis of differentiated vs. undifferentiated cells resulted in fold increase of ADMSCs for each type of cells; 3.4±0.5 for osteoblasts, 2.6±0.7 for adipoblasts and 3.3±0.6 for chondroblasts (Figure 2 A, B & C respectively).

Immunophenotypic characterization (RT-PCR)

In Adipogenic culture conditions a transcription factor was identified (Figure 3). Figure 3A shows amplification plot of leptin expression at 4,7,14 days. ADMSCs expressed lipoprotein lipase (Figure 3B), leptin (Figure 3C) and adiponectin (Figure 3D) as demonstrated by Gel electrophoresis. For osteocytic gene markers expression, under human adipose osteogenesis culture conditions ADMSCs expressed osteocalcin at different time intervals of 4, 7, 14 and 21 days (Figure 4).

Figure 3: ADMSCs differentiation demonstrated adipogenic differentiation by RT-PCR analysis of genes markers expression; (A) Amplification Plot of adipocytic marker gene (Leptin) at 4, 7, 14, 21 days. (B) Agarose gel electrophoresis showing positive expression of lipoprotein lipase at day 7 by RT-PCR. (C) Agarose gel electrophoresis showing positive expression of leptin at day 7, 14, 21 by RT-PCR. (D) Agarose gel electrophoresis showing positive expression of adiponectin.

Figure 4: ADMSCs differentiation demonstrated osteogenic differentiation by RT-PCR analysis of genes markers expression; Amplification Plot of osteogenic marker gene (osteocalcin) at 4, 7, 14, 21 days.
Phenotypic analysis

We carried on further characterization of ADMSCs. Fluorescence-activated cells confirmed the endogenous expression of the most important surface markers for MSCs; CD90, CD29, CD105 and CD13. On the other hand, those rarely expressed CD34 and CD14 showed negative results (Figure 5).

ADMSCs’ protective effect against renal impairment caused by cisplatin

Evaluated by serum creatinine, BUN and creatinine clearance (Table 2). I.P injection of 5 mg/kg cisplatin induced significant increases in serum creatinine and BUN, which peaked at days 4 and 7 and declined at days 11.

They stabilized at the 30th day to values slightly higher than baseline. Meanwhile, intravenous injection of 5×10⁵ MSC on day 1 after receiving cisplatin strongly protected renal function at days 4, 7, 11 and 30 as reflected by significantly lower serum creatinine and BUN values in comparison to cisplatin-treated rats that were given fresh culture media intravenously. Figure 6A indicates the long-term protective effect of ADMSCs on kidney function in term of creatinine clearance.

Cisplatin increased renal tissue MDA detectable at days 4, 7, 11 and 30. Intravenous injection of 5×10⁶ MSC into the rats on day 1 after receiving cisplatin induced significant decrease in MDA measured at days 4, 7, 11 and 30 when compared with cisplatin-injected rats treated with fresh culture media via tail vein. ADMSCs increased significantly, the renal tissue homogenate GSH and SOD levels content which was demonstrated in MSCs group at all intervals when compared to the non-treated groups. Figure 6B indicates the protective effect of ADMSCs on kidney function in the term of MDA on the long term.

ADMSCs reduced renal injury caused by cisplatin on long-term study

Evaluated by H&E that was performed on the kidney sections. Regenerative changes were found as early as the 4th day in addition to less tubular necrosis and atrophy than in cisplatin injected rats (Group I) and cisplatin injected rats treated with culture media through tail vein (Group III). Moreover, the ADMSCs continued to offer protection to renal tissue and ameliorate renal injury until the 30th day.

The detailed histological changes were observed in kidney tissue samples at the different time intervals (Figure 7 A & B) (Table 3):

**Figure 5:** Flow cytometry analysis of surface markers on cultured human adipose tissue mesenchymal stem cells revealed that their expression of surface antigens such as CD29 (94%), CD 90 (92%), CD 105 (92%) and CD13 (89%). (Passage 4:8) was strongly positive; but CD14 (4%) and CD34 (6%) was negative.
Renal anti-injury activity of ADMSCs in cisplatin-induced nephrotoxicity

Table 2: ADMSCs’ effects on renal function and tissue oxidative stress markers level in cisplatin-induced nephrotoxicity on long term. (mean ± SD)

|                  | Control        | Cisplatin      | Cisplatin+C.Medium | Cisplatin+SCs          |
|------------------|----------------|----------------|-------------------|------------------------|
| **S. Creatinine**|                |                |                   |                        |
| Day 4            | 0.47±0.11      | 1.92±0.04*     | 1.89±0.12*        | 1.02±0.11*             |
| Day 7            | 0.48±0.13      | 1.61±0.06†     | 1.62±0.04‡        | 0.85±0.11*             |
| Day 11           | 0.48±0.18      | 0.97±0.14*†    | 0.98±0.18*‡       | 0.70±0.08*†            |
| Day 30           | 0.43±0.11      | 0.76±0.04*‡    | 0.79±0.05*‡       | 0.56±0.07*‡            |
| **Cr.Clearance** |                |                |                   |                        |
| Day 4            | 1.600±0.860    | 0.007±0.002*   | 0.008±0.002*      | 0.017±0.009*           |
| Day 7            | 1.600±0.760    | 0.014±0.001*‡  | 0.012±0.003*‡     | 0.045±0.012*           |
| Day 11           | 1.600±0.790    | 0.054±0.016*†  | 0.056±0.020*‡     | 0.650±0.117* †         |
| Day 30           | 1.600±0.350    | 0.340±0.240*‡  | 0.360±0.320*‡     | 0.860±0.243* †         |
| **S.BUN**        |                |                |                   |                        |
| Day 4            | 054.36±0.31    | 266.70±08.70*  | 265.30±08.60*     | 197.80±07.67*          |
| Day 7            | 053.39±0.51    | 228.70±18.00*  | 236.00±15.00*‡    | 076.40±04.30* †        |
| Day 11           | 054.43±0.91    | 137.40±14.70*  | 138.60±16.30*‡    | 068.34±04.60* †        |
| Day 30           | 054.55±0.62    | 111.46±11.50*  | 112.58±08.40*‡    | 068.34±04.60* †        |
| **MDA tissue**   |                |                |                   |                        |
| Day 4            | 14.50±3.43     | 67.40±3.40*    | 69.50±4.80*       | 34.20±8.54*            |
| Day 7            | 14.50±3.89     | 65.10±4.54*    | 63.20±3.87*       | 25.40±2.86* †          |
| Day 11           | 14.60±2.56     | 34.10±4.70*‡   | 37.20±4.60*‡      | 17.30±3.82* †          |
| Day 30           | 14.50±2.46     | 32.80±3.10*‡   | 33.20±5.40*‡      | 16.32±3.65* †          |
| **Tissue GSH**   |                |                |                   |                        |
| Day 4            | 5.36±0.17      | 0.26±0.03*     | 0.27±0.05*        | 0.77±0.03*             |
| Day 7            | 5.38±1.15      | 0.53±0.04*     | 0.56±0.05*        | 2.56±0.05* †           |
| Day 11           | 5.35±0.18      | 1.38±0.42*‡    | 1.35±0.35*‡       | 3.53±0.21*‡            |
| Day 30           | 5.39±0.35      | 1.92±0.04*‡    | 1.95±0.08*‡       | 4.12±0.22*‡            |
| **Tissue SOD**   |                |                |                   |                        |
| Day 4            | 20.86±1.24     | 3.25±0.64*     | 3.70±0.65*        | 6.85±0.52*             |
| Day 7            | 20.82±1.64     | 6.24±0.57*     | 6.46±0.62*‡       | 10.67±0.38* †          |
| Day 11           | 20.78±1.28     | 9.96±0.30*‡    | 9.94±0.52*‡       | 15.62±0.43* †          |
| Day 30           | 20.73±0.84     | 15.24±0.46*‡   | 15.43±0.52*‡      | 18.67±0.42*‡           |

Significant difference compared to corresponding * control, ° cisplatin groups
Significant difference compared to intra-group day4, † day7, ‡ day11* by Kruskal-Wallis test at P≤0.05
Figure 6: ADMSCs effect on A] creatinine clearance and on B] renal tissue MAD level in cisplatin induced AKI at different time intervals.

Figure 7: Long-term ADMSCs effects on Renal Histopathology and Scoring in cisplatin- induced nephrotoxicity (mean ± SD): Day 4  A) Sections taken from cisplatin injected rats (group I) after 4 days revealed marked necrotic and degenerative changes in the OSOM where the tubules are dilated with thin denuded lining epithelium. Degenerative changes with apoptosis and shedding of tubular cells in about 90% of the tubules. Mild regenerative changes were also detected in OSOM in the form of some regenerating tubules (5%) lined by large cells with prominent nucleoli and with occasional mitotic figures. No solid sheets were detected. B) In ADMSCs injected group VI, less degenerative changes with less complete tubular necrosis. Regenerative changes were markedly detected in the OSOM in the form of many regenerating tubules (70-80%) lined by large cells with large hyperchromatic active nuclei with few solid sheets (less than 1/20 HPF). (HX&Ex 100).
### Table 3: ADMSCs effect on acute renal injury, regenerative and chronicity scores in the outer stripe of the outer medulla of rat kidney after cisplatin (n = 5 in each group for each time subgroup; mean ± SD)

|                  | Control | Cispl. | Cispl. + C.Medium | Cispl. + ADMSC |
|------------------|---------|--------|-------------------|----------------|
| **Necrotic tub.**|         |        |                   |                |
| 4                | 0.0±0.0 | 12.6±2.1* | 8.4±1.7*         | 3.9±0.3*       |
| 7                | 0.0±0.0 | 8.6±1.3* | 8.3±1.5*         | 4.6±0.4*       |
| 11               | 0.0±0.0 | 7.4±1.8* | 7.5±2.2*         | 2.6±0.2*       |
| 30               | 0.0±0.0 | 4.7±0.1* | 2.4±0.3*         | 1.0±0.6*       |
| **Inflam. cells**|         |        |                   |                |
| 4                | 0.0±0.0 | 8.8±1.3* | 8.4±1.6*         | 1.8±0.2*       |
| 7                | 0.0±0.0 | 8.4±1.6* | 8.3±1.9*         | 1.5±0.3*       |
| 11               | 0.0±0.0 | 8.5±1.1* | 8.1±1.5*         | 0.0±0.0*       |
| 30               | 0.0±0.0 | 4.7±0.2* | 4.4±0.3*         | 0.0±0.0*       |
| **Reg. Tub.**    |         |        |                   |                |
| 4                | 0.0±0.0 | 0.0±0.0 | 0.0±0.0           | 1.2±0.2*       |
| 7                | 0.0±0.0 | 0.0±0.0 | 0.0±0.0           | 2.7±0.2*       |
| 11               | 0.0±0.0 | 0.0±0.0 | 0.0±0.0           | 7.5±1.6*       |
| 30               | 0.0±0.0 | 1.4±0.2* | 1.6±0.3*         | 7.4±2.9*       |
| **Mitosis**      |         |        |                   |                |
| 4                | 0.0±0.0 | 0.0±0.0 | 0.0±0.0           | 2.2±0.8*       |
| 7                | 0.0±0.0 | 0.0±0.0 | 0.0±0.0           | 3.7±0.2*       |
| 11               | 0.0±0.0 | 1.7±0.2* | 1.5±0.3*         | 4.5±0.3*       |
| 30               | 0.0±0.0 | 1.7±0.2* | 1.5±0.2*         | 4.9±0.9*       |
| **Solid Sheets** |         |        |                   |                |
| 4                | 0.0±0.0 | 0.0±0.0 | 0.0±0.0           | 2.8±0.8*       |
| 7                | 0.0±0.0 | 0.0±0.0 | 0.0±0.0           | 4.8±0.6*       |
| 11               | 0.0±0.0 | 0.0±0.0 | 0.0±0.0           | 5.7±0.5*       |
| 30               | 0.0±0.0 | 1.3±0.2* | 1.4±0.4*         | 6.9±2.8*       |
| **Int. Fibrosis**|         |        |                   |                |
| 4                | 0.0±0.0 | 0.0±0.0 | 0.0±0.0           | 0.0±0.0        |
| 7                | 0.0±0.0 | 23.7±0.91* | 23.1±1.4*       | 4.6±0.3*       |
| 11               | 0.0±0.0 | 34.2±1.3* | 32.8±2.3*        | 11.9±1.8*      |
| 30               | 0.0±0.0 | 47.6±2.6* | 43.7±2.7*        | 17.8±1.7*      |
| **Atrophic Tub.**|         |        |                   |                |
| 4                | 0.0±0.0 | 13.3±2.3* | 12.5±1.4*       | 6.5±0.3*       |
| 7                | 0.0±0.0 | 12.7±1.2* | 12.5±1.3*       | 4.7±0.4*       |
| 11               | 0.0±0.0 | 12.4±0.8* | 12.3±0.6*       | 3.8±1.8*       |
| 30               | 0.0±0.0 | 4.4±0.2* | 4.6±0.2*         | 2.8±0.6*       |

Significant difference compared to corresponding * control, ° cisplatin groups &
Significant difference compared to intragroup day4†, day7‡, day11● by Kruskal-Wallis test at P≤0.05
Day 4:
Sections taken from cisplatin-injected rats (Group II) and cisplatin-injected rats treated with culture media through tail vein (Group III) after 4 days revealed marked degenerative changes mainly in OSOM. It varied from tubular cell vacuolar degeneration, up to complete tubular necrosis with apoptosis and shedding of tubular cells in about 90% of the tubules. Mild regenerative changes were also detected in OSOM in the form of some regenerating tubules (5%) lined by large cells with prominent nucleoli and with occasional mitotic figures. No solid sheets were detected.

In ADMSCs injected group VI, regenerative changes were markedly detected in the OSOM and ISOM in the form of many regenerating tubules (70-80%) lined by large cells with large hyperchromatic active nuclei with few solid sheets (less than 1/20 HPF).

Day 7:
Sections from cisplatin injected (Group II) and cisplatin-injected rats treated with culture media through tail vein (Group III) on 7th day showed pathological features mainly in the OSOM in the form of combined degenerative and regenerative changes. The degenerative changes predominated representing about 90% of all studied fields in this group. They varied from tubular cell vacuolar degeneration up to complete tubular necrosis with pyknosis and shedding of tubular cells. The regenerative changes detected in about 20% of all fields examined in the group, varied from tubular cell enlargement, mitosis and interstitial solid sheet formation.

Sections obtained from cisplatin-injected rats and ADMSCs (Group VI) sacrificed on the 7th day showed less marked degenerative changes in OSOM. The degenerative changes varied from tubular cell vacuolar degeneration, up to complete tubular necrosis with apoptosis and shedding of tubular cells in about 60-70% of the tubules.

Regenerative changes detected in both outer and inner medulla were in the form of many interstitial solid sheets (12/10 HPF) and tubules lined by large cells with prominent nucleoli with occasional mitosis.

Day 11:
Kidney sections obtained from cisplatin-injected rats (Group II) and cisplatin-injected rats injected with culture media through tail vein (Group III) on the 11th day revealed that the degenerative changes were more marked. The degenerative changes varied from tubular cell vacuolar degeneration, up to complete tubular necrosis with apoptosis and shedding of tubular cells in more than 80 - 90% of the tubules. In addition, there was mild interstitial round cell infiltrate. Regenerative changes were also detected and varied from tubular cell enlargement with regenerative atypia, mitosis and interstitial solid sheets (5/10 HPF).

Kidney sections obtained from cisplatin-injected rats treated with ADMSCs via tail vein (Group VI) and sacrificed on the 11th day revealed necrotic tubules (about 1 tubule /HPFs) with epithelial shedding and tubular dilatation. Regenerative changes were detected in the form of solid sheets having prominent bulging nuclei (about 1/10 HPFs), mitosis (less than 1/10HPFs) and regenerating tubules were detected in one rat of the group. The interstitium was the seat of focal round cell infiltration in one rat.

Day 30:
Sections obtained on day 30 from cisplatin-injected rats (Group II) and cisplatin injected and treated with culture media through tail vein (Group III) revealed occasional regenerating large tubules in the OSOM lined by large cells with prominent nucleoli and occasional mitotic figures (1/10HPFs). There was mild peritubular and perivascular fibrosis (about 5-10% of all fields).

Sections from kidney samples obtained from cisplatin-injected rats

---

Figure 8: ADMSCs protective effect for renal tubules from cisplatin induced AKI at different time intervals. Histological changes observed in kidney tissue samples at different time intervals identified the variation in (A) inflammatory cell infiltration, (B) Necrotic tubules.
treated with ADMSCs via tail vein (Group VI) and sacrificed on the 30th day showed significantly less cholestasis in regard to the tubular atrophy and the renal fibrosis, when compared with the cisplatin groups. The effect of ADMSCs on renal structure in term of inflammatory cell infiltration and on the necrotic tubules indicate their long-term protective activity (Figure 8 A & B).

Discussion

Several human malignancies are largely managed with cisplatin. However, in the setting of nephrotoxicity, which is one of the serious side effects of cisplatin, its clinical use as a chemotherapeutic agent is largely limited. Cisplatin acts on multiple cellular targets and hence, blocking its effect on a single target may only offer partial protection against nephrotoxicity(41).

Although the clinical management of AKI patients has significantly improved in recent years, we still lack specific therapies to enhance kidney repair. Recovery after acute injury is critical for patient morbidity and mortality in the hospital setting(16). The emerging field of regenerative medicine is progressing rapidly and supported by a large number of studies which have demonstrated the capacity of stem cells to substitute for the damaged or lost differentiated cells in various organs and tissues(17-22).

Few studies have discussed the use of cord blood and bone marrow MSCs for the management of AKI models(23-28). In addition, the ability of adipose tissue derived stromal cells to ameliorate the AKI induced via cisplatin has been reported(29).

Reviewing the literature, some published studies have reported the impact of MSCs on cisplatin induced AKI(27-29). Shaohua and Dongcheng’s study in 2013(27) was based on rat BMSCS, while Weique et al. 2015(28) and Kim et al. 2015(29) studies were based on human ADMSCs. The latter reported that ADMSCs exert aparacrine protective effect on cisplatin nephrotoxicity and suggested that human ADMSCs might be a new therapeutic approach for patients with acute kidney injury. Many points distinguish our work from these studies as follows; (1) all of the previous studies evaluated the protective effect of MSCs only for a short duration (only the acute effect for 3 to 5 days of cisplatin induced AKI). While our work, in addition to evaluating the short duration effect, has evaluated the long term protective effect ( the chronic effect) (2) the sample size used in those studies was noticeably small while our work included a large sample size, (3) these studies identified renal protective effect of MSCs only using biochemical renal function analyses and renal histology. An important parameter in our work, was the assessment of the oxidative stress in kidney tissue for evaluating the ADMSCs’ protective effect (4) In addition, through scoring of different histopathological findings, this study tried to evaluate both the protective and the regenerative activities of ADMSCs by correlating them to the biochemical parameters.

The damaging effect of cisplatin on the kidney comprises of complex interrelated sequence of events eventually resulting in both apoptosis and necrosis of the renal cells(31). Thus, an ideal modality to manage cisplatin nephrotoxicity should work by multiple mechanisms.

The aim of our study was to address the role of ADMSCs in AKI secondary to cisplatin administration where 80 rats were divided into four equal groups: positive control (cisplatin injected); negative control (saline injected group); (cisplatin injected and culture media treated) and (cisplatin injected and ADMSCs treated) group.

Moreover, in each group, rats’ were subgrouped based on day of sacrifice on day 4, day 7, day 11 and day 30 to study the evolution of ADMSCs activity on the acute injury, regenerative activity and the tissue chronicity events induced by cisplatin separately. In our study, the use of ADMSCs was capable of ameliorating renal dysfunction; as demonstrated by improvement of serum creatinine, creatinine clearance and improvement of the histological indices of injury in the renal cortex and outer medulla.

ADMSCs rapidly ameliorated and protected the kidneys in-group IV starting from day 4 (Figure 8). Regeneration of the tubular cells under the influence of ADMSCs cannot explain the recovery. There was markedly less necrotic changes in spite of only 1/20 HPF interstitial solid sheets. The possible explanation could be through the paracrine effect of the ADMSCs as previously demonstrated by numerous studies, which have shown that organ protection by administered stem cells is primarily due to paracrine mechanisms rather than the replacement of damaged cells by differentiated stem cells(27-31).

Other workers studying the ADMSCs role in cisplatin induced AKI(8-9) have reached to the same conclusion. They suggested that ADMSCs might exert beneficial paracrine actions on the injured kidney by releasing biologically active factors where they used a culture media from cultured ADMSCs. Co-culturing ADMSCs or culture media of ADMSCs with proximal renal tubular cells, protected cultured human renal proximal tubular cells from cisplatin toxicity(25).

Reactive oxygen species are important mediators exerting toxic effects on various organs including the kidney where Chin et al. 2015(30) concluded that ADMSCs administration minimized the AKI through suppression of the inflammatory response and the oxidative stress. This possible mechanism of renal protection was also demonstrated in our study where the use of ADMSCs partially suppressed oxidative stress and lipid peroxidation as reflected by decrease in the level of Malondialdehyde. Concomitantly ADMSCs increased superoxide dismutase and glutathione reductase in the renal tissue.

Our data indicate the ability of ADMSCs to protect against an advanced acute tubular necrosis as that detected in the control positive group of cisplatin. In addition, in spite of an early single dose of ADMSCs, this group of rats had developed a significant regenerative activity extending until day 30 with limited fibrotic activity. These observations raise the importance of latter booster doses of ADMSCs.

Interestingly, ADMSCs treated group of rats’ showed highly important parallel improvement in renal tissue oxidative stress markers with the acute injury morphological scores (Table2; Figure 6B) better than with the creatinine clearance (Figure 6A) when compared with the control positive group. This improvement was of many folds with GSH as compared with the cisplatin group, indicating a key role of GSH in protecting against cisplatin induced acute tubular necrosis. The latter finding raises the question about the molecular mechanism of ADMSCs in promoting GSH. In addition, the early-administered single dose of ADMSCs seems to exercise long-term beneficial activity. This observation needs further exploration in regard to the probable interaction between the exogenously administered stem cells and the endogenous stem cells.

In conclusion, ADMSCs represent an easy practical source of stem cells. They have both protective and regenerative activities with consequent limitation of the development of renal fibrosis on top of the cisplatin induced acute tubular necrosis. Proposed anti-oxidative activity mediated through GSH activity promotion has an important role. The chronicity of the histopathological scoring indicates a promising advantage for a late booster dose of ADMSCs.
Renal anti-injury activity of ADMSCs in cisplatin induced nephrotoxicity

References

1. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008; 73 (9): 994–1007.
2. Herrera MB, Bussolati B, Bruno S, Fonsato V, Romanazzi GM, Camussi G. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med 2004; 14 (6): 1035–41.
3. Kunter U, Rong S, Djuric Z, Boor P, Müller-Newen G, Yu D, Floege J. Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol 2006; 17 (8): 2202–12.
4. Ling SI Y, LiZhao Y, Hao HJ, BingFu X, Han WD. MSCs: Biological characteristics, clinical applications and their outstanding concerns. Ageing Research Reviews 2011; 10 (1): 93-103.
5. Bassi G, Pacelli L, Carusone R, Zanoncellojasmin, Krampera M. Adipose-derived stromal cells (ASCs). Transfusion and Apheresis Science 2012; 47 (2): 193–8.
6. Zuk PA. Stem cell research has only just begun. Science 2001; 293(5528):211–12.
7. Shaohua QI, Dongcheng WU. Bone marrow-derived mesenchymal stem cells protect against cisplatin-induced acute kidney injury in rats by inhibiting cell apoptosis. International Journal of Molecular Medicine 2013; 32 (6): 1262-72.
8. Weiqi Yao, Qinyong HU, Yuhong MA, Wenping Xiong, Tingting WU, Jun CAO, Dongcheng WU. Human adipose-derived mesenchymal stem cells repair cisplatin-induced acute kidney injury through anti-apoptotic pathways. Exp Ther Med. 2015;10(2):468-476.
9. Kim JH, Park DJ, Yun JC, Jung MH, Yeo HD, Kim HJ, Kim DW, Yang HJ, Lee GW, Jeong SH, Roh GS, Chang SH. Human adipose tissue-derived mesenchymal stem cells protect kidneys from cisplatin nephrotoxicity in rats. Am J Physiol Renal Physiol. 2012; 1; 302(9):F1141-50.
10. Bannell BA, Flaat M, Gagliardi C, Patel B, Ripoll C. Adipose-derived stem cells: isolation, expansion and differentiation. Methods 2008; 45(2):115-20.
11. Phinney DG, Kopen G, Isaacson RL & Prockop DJ. Plastic adherent stromal cells from the bone marrow of commonly used strains of inbred mice: variations in yield, growth, and differentiation. J Cell Biochem 1999; 72(4):570–85.
12. Rombout WJ, Ploemacher RE. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia 2003; 17(1): 160-70.
13. Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, Prockop DJ. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 2004; 103(5): 1662-68.
14. Collins TJ. Image J for microscopy. BioTechniques 2007; 43 (1 Suppl): 25–30.
15. Van Roeyen CR, Ostendorf T, Denecke B, Bokemeyer D, Behrmann I, Strutz F, Lichenstein HS, LaRochelle WJ, Pena CE, Chaudhuri A, Floege J. Biological responses to PDGF-BB versus PDGF-DD in human mesangial cells. Kidney Int. 2006; 69(8): 1393–1402.
16. Bussolati B, Tetta C, Camussi G. Contribution of Stem Cells to Kidney Repair Am J Nephrol 2008;28(5):813–22.
17. Donovan P, Gearhart J. The end of the beginning for pluripotent stem cells. Nature 2001; 414: 92–97.
18. Goodell M. Stem-cell ‘plasticity’: befuddled by the muddle. Curr Opin Hematol 2003; 10(3): 208–13.
19. Herzog E, Chai L, Krause D. Plasticity of marrow-derived stem cells. Blood 2003; 102(10): 3483–93.
20. Weissman I. Stem cells: units of development, units of regeneration, and units of evolution. Cell 2000; 100(1): 157–68.
21. Epicump P, Detry O, Weekers L, Bonvoisin C, Lechanteur C, Briquet A, Yves Beguin Y, Krzesinski J-M, Jouret F. Mesenchymal stromal cell therapy in conditions of renal ischaemia/reperfusion. Nephrol Dial Transplant. 2014; 29(8):1487–93.
22. Zou X, Zhang G, Cheng Z, Yin D, Du T, Ju G, Miao S, Liu G, Lu M, Zhu Y. Microvesicles derived from human Wharton’s Jelly: mesenchymal stromal cells ameliorate renal ischemia-reperfusion injury in rats by suppressing CX3CL1. Stem Cell Research & Therapy 2014, 5(2):40-53.
23. Morigi M, Imberti B, Zoja C, Coma D, Tomasoni S, Abbate M, Rottoli D, Angioletti S, Benigni A, Perico N, Alison M, Remuzzi G. Mesenchymal stem cells are renotrophic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 2004; 15(7): 1794–1804.
24. Morigi M, Introna M, Imberti B, Coma D, Abbate M, Rota C, Rottoli D, Benigni A, Perico N, Zoja C, Rambaldi A, Remuzzi A, Remuzzi G. Human bone marrow-mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells 2008; 26(8): 2075–82.
25. Morigi M, Rota C, Montemurro T, Montelatici E, Lo Ciceri V, Imberti B, Abbate M, Zoja C, Cassis P, Longaretti L, Rebulla P, Introna M, Capelli C, Benigni A, Remuzzi G, Lazzari L. Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury. Stem Cells 2010; 28(3): 513–22.
26. Bi B, Schmitt R, Isailova M, Nishio H, Cantley LG. Stromal cells protect against acute tubular injury via an endocrine effect. Am Soc Nephrol 2007; 18(9): 2486–96.
27. Ginecchi M, He H, Liang OD, Melo LG, Morelli F, Mu H, Noisieux N, Zhang L, Pratt RE, Ingwall JS, Dzau VJ. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005; 11(4): 367–68.
28. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, Epstein SE. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004; 94(5): 678–85.
29. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, Fuchs S, Epstein SE. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004; 109(12): 1543–49.
30. Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005; 289(1): F29-30.
31. Chen YT, Sun CK, Lin YC, Chang LT, Chen YL, Tsai TH, Chung SY, Chua S, Kao YH, Yen CH, Shao PL, Chang KC, Leu S, Yip HK. Adipose-derived mesenchymal stromal cell protects kidneys against ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. J Transl Med. 2011; 9:51.
Abbreviations

h-ADMSCs: Human-Adipose Derived Mesenchymal Stem Cells
AKI: Acute Kidney Injury
BUN: Blood Urea Nitrogen
MDA: Malondialdehyde
SOD: Superoxide dismutase
GSH: Reduced Glutathione
PBS: Phosphate-Buffered Saline
DMEM: Dulbecco’s Modified Eagle’s Medium
FBS: Fetal Bovine Serum
FACS: Fluorescence-Activated Cell Sorting
CFU-F: Colony Forming Unit-Fibroblast
RT–PCR: Real-Time quantitative Reverse Transcriptase-Polymerase Chain Reaction
ALBP: Adipocyte Lipid-Binding Protein
OSOM: Outer Strip of Outer Medulla
ISOM: Inner Strip of Outer Medulla

Potential Conflicts of Interests

None

Acknowledgements

This work was supported by Science and Technology Development Fund (STDF), grant number 1061, Ministry of Scientific Research, Egypt.

Corresponding Author

Mohamed-Ahdy A.A. Saad, Faculty of Medicine, Mansoura University, Mansoura, Egypt; E-mail: ahady2007@yahoo.com